Healthcare -
Medical - Devices - NASDAQ - US
$ 5.49
3.49 %
$ 208 M
Market Cap
-4.85
P/E
1. INTRINSIC VALUE
Balance Sheet
TriSalus Life Sciences, Inc.
| Current Assets | 20.7 M |
| Cash & Short-Term Investments | 8.52 M |
| Receivables | 5.09 M |
| Other Current Assets | 7.06 M |
| Non-Current Assets | 3.3 M |
| Long-Term Investments | 350 K |
| PP&E | 2.66 M |
| Other Non-Current Assets | 288 K |
| Current Liabilities | 10.2 M |
| Accounts Payable | 2.27 M |
| Short-Term Debt | 216 K |
| Other Current Liabilities | 7.74 M |
| Non-Current Liabilities | 39.6 M |
| Long-Term Debt | 23.4 M |
| Other Non-Current Liabilities | 16.2 M |
EFFICIENCY
Earnings Waterfall
TriSalus Life Sciences, Inc.
| Revenue | 29.4 M |
| Cost Of Revenue | 4.1 M |
| Gross Profit | 25.3 M |
| Operating Expenses | 61.5 M |
| Operating Income | -36.2 M |
| Other Expenses | -6.12 M |
| Net Income | -30 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
TriSalus Life Sciences, Inc.
| Net Income | -30 M |
| Depreciation & Amortization | 744 K |
| Capital Expenditures | -345 K |
| Stock-Based Compensation | 5.44 M |
| Change in Working Capital | -9.55 M |
| Others | -9.38 M |
| Free Cash Flow | -41.2 M |
Wall Street Analysts Price Targets
TriSalus Life Sciences, Inc.
Wall Street analysts predict an average 1-year price target for TLSI of $11 , with forecasts ranging from
a
low of
$10 to a high of $12 .
TLSI Lowest Price Target
Wall Street Target
10 USD
82.15%
TLSI Average Price Target
Wall Street Target
11 USD
100.36%
TLSI Highest Price Target
Wall Street Target
12 USD
118.58%
4. DIVIDEND
ANALYSIS
TLSI does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
TriSalus Life Sciences, Inc.
Sold
0-3 MONTHS
129 K USD 4
3-6 MONTHS
0 USD 0
6-9 MONTHS
112 K USD 2
9-12 MONTHS
49.5 USD 1
Bought
0 USD 0
0-3 MONTHS
673 K USD 4
3-6 MONTHS
145 K USD 2
6-9 MONTHS
24.8 K USD 1
9-12 MONTHS
7. News
TriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), which seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, is excited to announce the launch of the TriNav® FLX Infusion System, the latest addition to the TriNav Portfolio. TriNav FLX, with enhanced trackability, significantly expands our existing portfolio of TriNav pr.
businesswire.com
- 1 week ago
TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces the appointment of David B. Patience as Chief Financial Officer, effective July 1, 2025. Mr. Patience succeeds James Young, who stepped down for personal reasons effective May 30, 2025. Dan Giordano, Vice Presi.
businesswire.com
- 2 weeks ago
TriSalus Life Sciences, Inc. (TLSI) Q1 2025 Earnings Conference Call Transcript
TriSalus Life Sciences, Inc. (TLSI) Q1 2025 Earnings Conference Call Transcript
seekingalpha.com
- 1 month ago
TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates
TriSalus Life Sciences, Inc. (TLSI) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.54 per share a year ago.
zacks.com
- 1 month ago
TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance.
businesswire.com
- 1 month ago
TriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference Call
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies, announced today that it will host a conference call and webcast on Thursday May 15, 2025 at 8:00 AM eastern time to discuss its financial results for the quarter ended March 31, 2025. A press release detailing the results.
businesswire.com
- 1 month ago
TriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock?
TriSalus Life Sciences, Inc. (TLSI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
zacks.com
- 2 months ago
TriSalus Life Sciences: Optimistic Guidance For 2025, But There Are Still Risks
TriSalus Life Sciences aims to achieve positive cash flow by 2025, driven by expanding sales of their TriNav system and reducing operating expenses. The PERIO-03 trial for nelitolimod, a potential treatment for liver-involved cancers, is a key catalyst, with top-line data expected later this year. Financially, TLSI reported a net loss of $30 million for FY 2024, but expects to be EBITDA positive with 50% sales growth in 2025.
seekingalpha.com
- 2 months ago
TriSalus Life Sciences, Inc. (TLSI) Q4 2024 Earnings Call Transcript
TriSalus Life Sciences, Inc. (NASDAQ:TLSI ) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Jeremy Feffer - Managing Director, LifeSci Advisors Mary Szela - President & Chief Executive Officer James Young - Chief Financial Officer Richard Marshall - Medical Director Conference Call Participants Carl Burns - Northland Capital Markets Justin Walsh - JonesTrading Frank Takkinen - Lake Street Capital Markets Suraj Kalia - Oppenheimer & Company William Plovanic - Canaccord Genuity Operator Good morning, and welcome to TriSalus Life Sciences Fourth Quarter and Full Year 2024 Earnings Conference Call. Currently, all participants are in a listen-only mode.
seekingalpha.com
- 2 months ago
TriSalus Life Sciences, Inc. (TLSI) Reports Q4 Loss, Tops Revenue Estimates
TriSalus Life Sciences, Inc. (TLSI) came out with a quarterly loss of $0.35 per share in line with the Zacks Consensus Estimate. This compares to loss of $1.56 per share a year ago.
zacks.com
- 2 months ago
TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences Inc., (Nasdaq: TLSI), oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and with our investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications, today announced its financial results for the fourth quarter and full yea.
businesswire.com
- 2 months ago
TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav® Infusion System Mapping
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), which seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today that the Centers for Medicare & Medicaid Services (CMS) has established a new Level II HCPCS code for the TriNav® Infusion System, effective April 1, 2025. This new code, C8004, provides reimb.
businesswire.com
- 2 months ago
8. Profile
Summary
TriSalus Life Sciences, Inc. TLSI
COUNTRY
US
INDUSTRY
Medical - Devices
MARKET CAP
$ 208 M
Dividend Yield
0.00%
Description
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.
Contact
6272 West 91st Avenue, Westminster, CO, 80031
https://trisaluslifesci.com
IPO
Date
Feb. 8, 2021
Employees
110
Officers
Ms. Jennifer L. Stevens J.D.
Chief Regulatory Officer
Dr. Bryan F. Cox Ph.D.
Chief of Research
Dr. Richard B. Marshak M.B.A., MBA, VMD
Chief Commercial Officer
Mr. James E. Young
Chief Financial Officer, Secretary & Treasurer
Ms. Lori Ann Santamaria
Vice President of Operations
Ms. Jodi Devlin
Chief of Clinical Strategy & Operations
Ms. Mary T. Szela B.S.N., M.B.A.
Chief Executive Officer, President & Director